Head to Head Contrast: Kiora Pharmaceuticals (NASDAQ:KPRX) & PMV Pharmaceuticals (NASDAQ:PMVP)

Kiora Pharmaceuticals (NASDAQ:KPRX) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, valuation and risk.

Valuation & Earnings

This table compares Kiora Pharmaceuticals and PMV Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiora Pharmaceuticals	$16.02 million	0.42	$3.60 million	($2.09)	-0.87
PMV Pharmaceuticals	N/A	N/A	-$58.71 million	($1.60)	-0.84

Kiora Pharmaceuticals has higher revenue and earnings than PMV Pharmaceuticals. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are owned by institutional investors. 0.1% of Kiora Pharmaceuticals shares are owned by insiders. Comparatively, 7.6% of PMV Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility & Risk

Kiora Pharmaceuticals has a beta of -0.7, meaning that its share price is 170% less volatile than the S&P 500. Comparatively, PMV Pharmaceuticals has a beta of 1.54, meaning that its share price is 54% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for Kiora Pharmaceuticals and PMV Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiora Pharmaceuticals	1	1	1	0	2.00
PMV Pharmaceuticals	1	0	1	0	2.00

Kiora Pharmaceuticals currently has a consensus target price of $10.00, suggesting a potential upside of 449.45%. PMV Pharmaceuticals has a consensus target price of $5.00, suggesting a potential upside of 270.37%. Given Kiora Pharmaceuticals’ higher possible upside, equities research analysts plainly believe Kiora Pharmaceuticals is more favorable than PMV Pharmaceuticals.

Profitability

This table compares Kiora Pharmaceuticals and PMV Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kiora Pharmaceuticals	N/A	-36.35%	-25.82%
PMV Pharmaceuticals	N/A	-55.34%	-51.01%

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.